Objectives: We evaluated the effect of Ribavirin __ampersandsignndash; a broad spectrum virustatic agent, in the hospital stay of measles cases both with and without complications. Materials and Methods: This is a retrospective study where we examined the Bed Head Tickets of 100 randomly selected measles cases. One group was treated with Ribavirin along with antibiotic and other supportive measures and another group was treated with antibiotic and supportive measures only. We tried to evaluate the effect of Ribavirin on the hospital stay of Measles patients with or without complication. Results: We found that there was absolute reduction in hospital stay for Ribavirin group than group treated without Ribavirin (4.018 __ampersandsignplusmn; 1.92 days versus 6.934 __ampersandsignplusmn; 2 days. p= 0.4). Mean hospital stay of measles with pneumonia treated with Rivavirin was 3.909 __ampersandsignplusmn; 1.02 days among 22 cases which was 8.5 __ampersandsignplusmn; 2.5 days among 10 cases treated without Ribavirin. This reduction was statistically significant (p= 0.02). Mean hospital stay of 12 cases of measles with encephalitis treated with Ribavirin was 5__ampersandsignplusmn; 1.15 days while it was 8.16__ampersandsignplusmn;2.07 days for 6 patients received antibiotic and supportive measures only (p=0.35). Case fatality rate in Ribavirin group was 0 %, against 4.34% for the group without Ribavirin. Conclusion: Reduction in the hospital stay of measles cases even in those who had complications, is an encouraging finding. Further studies with large sample size and ramdomized controlled trials are required to evaluate the effectiveness of Ribavirin in measles along with other RNA viruses.